Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients

Phase 2

Completed

• Conditions: Congestive Heart Failure

• Registration Number: NCT00043771
• Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Brief Summary

Patients with congestive heart failure will be assessed for safety and clinical effects of Tolvaptan 30 mg every day versus 15 mg twice a day over a period of 7 days.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-05
• Study First Submitted: 2002-08-13
• Study First Submitted QC: 2002-08-13
• Study First Posted: 2002-08-14
• Status Verified: 2002-09
• Study Completion: 2002-09
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (9)

Central Cardiology Medical Clinic; 🇺🇸 Bakersfield, California, United States

Saint Louis University; 🇺🇸 St. Louis, Missouri, United States

University of California-San Diego; 🇺🇸 San Diego, California, United States

University of Miami/Jackson Memorial Hospital; 🇺🇸 Miami, Florida, United States

Medical University of South Carolina; 🇺🇸 Charleston, South Carolina, United States

University of Missouri-Kansas City School of Medicine; 🇺🇸 Kansas City, Missouri, United States

Medical Research Institute; 🇺🇸 Slidell, Louisiana, United States

Androscoggin Cardiology Associates; 🇺🇸 Auburn, Maine, United States

Cardiology of Oklahoma; 🇺🇸 Tulsa, Oklahoma, United States